Wellgistics Health walks into tonight's earnings report with one of the most dramatic short-selling buildups seen in the micro-cap space this year — a story told less by the level of short interest than by the speed of its return.
Short positioning has exploded. SI as a percentage of free float hit 26.2% on May 15, up from just 0.8% at the start of the month. That is a 32-fold increase in two weeks. The borrow market has tightened sharply alongside it: availability has collapsed from above 150% in late April to just 9.5% today, meaning roughly one share remains available for every ten already lent out. Cost to borrow, at 50.8% annualised, has more than doubled over the past week — though it remains well below the extreme levels seen in mid-April, when it peaked above 330%. The ORTEX short score has surged to 79.9, up from 51 at the start of May and ranking the stock in the first percentile of the broader universe on short positioning. What makes this pattern striking is its second leg: short sellers who retreated sharply through late April and early May have rebuilt positions at an even faster pace than their initial push.
The fundamental backdrop gives bears plenty to work with. The ORTEX stock score sits at just 33.6, with a quality sub-score of 21.4, an F-Score of zero, and a Z-Score of -7.56 — a level associated with severe financial distress. Return on assets is deeply negative at around -96%, and the stock has lost roughly 42% in the past month alone, closing at $0.0835 on May 15. Wellgistics has dramatically underperformed its health care distributor peers: Cencora, McKesson, and Cardinal Health have all traded flat-to-higher over the same period, underlining how stock-specific this pressure has been. Any bull case rests on a sharp operational inflection that the current metrics do not yet support.
The earnings history adds another layer of caution. The last four events produced an average first-day move of roughly -7%, with the two most recent prints delivering single-day drops of around 14%. Five-day reactions have been mixed but mostly negative, suggesting the market has consistently punished the release rather than rewarded it.
Tonight's print is therefore a test of whether the company can produce any financial signal — revenue trajectory, cash position, or path to profitability — capable of breaking the short sellers' conviction before borrow conditions tighten further.
See the live data behind this article on ORTEX.
Open WGRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
